Cimetidine amplifies the anti-neoplastic effect of Trichinella spiralis in mice. by Ruitenberg, E. J. et al.
Br. J. Cancer (1982) 45, 314
Short Communication
CIMETIDINE AMPLIFIES THE ANTI-NEOPLASTIC EFFECT
OF TRICHINELLA SPIRALIS IN MICE
E. J. RUITENBERG, W. KRUIZINGA, P. A. STEERENBERG,
A. ELGERSMA AND W. H. DE JONG*
From the Laboratory ofPathology, National Institute ofPublic Health, Bilthoven, The Netherlands
Received 20 July 1981 Accepted 7 October 1981
MAST-CELL MEDIATORS, including hista-
mine, exert a variety of pharmacological
effects, which can be explained by assum-
ing two kinds of receptors, designated Hi
and H2 (Rocklin et al., 1979). H2 receptors
have been shown on e.g. T lymphocytes,
their function being suppressed by hista-
mine.
In two recent papers (Osband et al.,
1981; Giffordetal., 1981) cimetidine, anH2-
receptor antagonist, was shown to possess
anti-neoplastic properties in mice. In the
experimental tumour models used, the
specific immunity, based on the presence
of cytotoxic T cells, was probably en-
hanced by the pharmacological blocking
effect ofcimetidine on H2-receptor-bearing
suppressor cells.
Experimental infections with the para-
sitic nematode Trichinella spiralis exert an
immunomodulating activity on responses
to unrelated antigens, including pathogens
and tumour cells. The immunomodulation
was reported to be connected to the in-
testinalphase(Ljungstrom & Huldt, 1977).
Furthermore, the intestinal phase (i.e.
the adult worm) is accompanied by a
marked intestinal mastocytosis (Ruiten-
berg & Elgersma, 1976). It has been
suggested that mast-cell proliferation,
IgE-triggered mediator release (including
histamine) and the ensuing hypersensitiv-
ity reaction might play a role in the regu-
lation of malignancies (Lynch et al., 1978).
Consequently, we tested the possibility
of the involvement of histamine in the
anti-neoplastic effect of T. spiralis on the
growth of a murine fibrosarcoma using an
H2-receptor antagonist (cimetidine) and
an H2-receptor agonist (tolazoline).
The mice used were conventional inbred
female BALB/c, 7-9 weeks of age, ob-
tained from the Central Institute for the
Breeding of Animals, TNO, Zeist, The
Netherlands. The tumour was a fibro-
sarcoma originally induced by 3-methyl-
cholanthrene in the same inbred strain.
The tumour was non-immunogenic and
non-metastasizing (Ruitenberg et al.,
1978). The T. spiralis strain was main-
tained in our Institute (Ruitenberg et al.,
1977). Tolazoline hydrochloride was ob-
tained from Brocacef Ltd, Maarssen, The
Netherlands. Cimetidine (Tagemet®) was
obtained from Smith, Kline and French,
Rijswijk, The Netherlands.
Groups of 8-10 mice were orally infected
with 200 T. spiralis larvae each, 8 days
before s.c. inoculation in the hind foot pad
of 5 x 105 tumour cells in 0 05 ml (Day 0).
Cimetidine (50 mg/kg) or tolazoline HC1
0 5 mg/kg were administered i.p. at Days
-8, -6, -4, -2, and 0. Dilutions were
prepared in saline. Tumour growth was
measured twice weekly. The number of
larvae and the intervals to tumour inocu-
lation were selected on the basis of
preliminary experiments in which a re-
producible regression was observed using
this schedule (unpublished data).
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FIGURE Modulationi of the anti-neoplastic effect of a T. spiralis infection on the growth of a fibro-
sarcoma in the foot of BALB/c mice by an H2 agonist (tolazoline) and an H2 antagonist
(cimetidine). T. sJ)iralis (200 larvae) given orally at Day -8. *P< 0.05, **P<.0-01, ***P< 0.001
(T. spiralis+antagonist vs T. spiralis). *--- agonist (tolazoline); * * control; *
antagonist (cimetidine); O- O T. spiralis; 0O-- O T. spiralis +agonist (tolazoline);
n---O T. spirlis8+antagonist (cimetidine).
Pre-infection with 200 T. spiralis larvae
caused tumour-growth retardation detect-
able as early as 5 days after tumour-cell
inoculation (Figure).
Cimetidine caused an additional tumour-
growth retardation visible from Day 5
onwards until the end of the experiment
(Day 19). Tolazoline did not influence the
Trichinella-induced tumour-growth retar-
dation. Both drugs alone had no effect on
tumour growth.
The actual mechanism of the immuno-
modulation caused by Trichinella is un-
known, but is connected with the intestin-
al phase (Ljungstrom & Huldt, 1977).
During this period also an anti-neoplastic
effect is observed. The intestinal phase is
accompanied by an increase in intestinal
mast cells (Ruitenberg & Elgersma, 1976).
There is no published evidence that
pharmacologically active mediators, in-
cluding histamine, are released during the
intestinal phase of Trichinella in the
mouse. However, since the H2-receptor
antagonist, cimetidine, increased the Tri-
chinella-induced tumour regression, but
had no effect on uninfected animals, a
possible relationship can be suggested. It
is conceivable that the anti-tumour effect
of Trichinella might be modulated by
parasite-induced suppressor T cells, known
to possess H2-receptors (Rocklin et al.,
1979), whose effect is blocked by the
H2-receptor antagonist cimetidine, which
increases the anti-neoplastic effect. Cime-
tidine alone exerted no anti-tumour effect.
This is probably due to the lack of sup-
pressor T-cell induction by the tumour
itself.
Although not studied in detail, cime-
tidine did not seem to exert any effect on
either worm expulsion or number of
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intestinal mast cells (data not presented).
Therefore, the cimetidine effectisprobably
due to its action on the H2-receptors on
the target cells, and not to a possibly
decreased histamine release by diminished
stimulation ofhistamine-containing cells.
We conclude that H2-receptor-bearing
cells partially suppress the anti-neoplastic
effect of Trichinella. In contrast to the
data presented by Osband et al. (1981) and
Gifford et al. (1981) cimetidine had no
direct anti-neoplastic effect in our tumour
model but amplified the parasite-induced
anti-tumour effect. These observations
further support the potential of cimetidine
in regulating immune responses, including
its role in cancer immunotherapy.
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